Spyre Therapeutics, Inc. SYRE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s total current liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported total current liabilities of $85.16M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s total current liabilities increased by 20.5% year-over-year, from $70.68M to $85.16M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total current liabilities has grown at a 29.0% compound annual growth rate (CAGR), from $16.44M to $58.69M.
- What does total current liabilities mean?
- The total amount of debt and other obligations due within one year.
- How do you interpret total current liabilities?
- Lower levels relative to current assets indicate a healthier liquidity position and reduced risk of financial distress.
- How does total current liabilities compare across companies?
- Investors compare this to cash and short-term investments to determine the company's net working capital position.